|
Cross-sectional associations at baseline between NT-proBNP (dependent variable) and rheumatoid arthritis disease activity |
||||
| Adjusted linear regression |
Multivariate linear regression |
|||
|
|
||||
| β coefficient |
P value |
β coefficient |
P value |
|
|
|
||||
| Age |
1.02 (1.01–1.03) |
< 0.001 |
1.009 (1.00–1.02) |
0.04 |
| Male gender |
0.74 (0.59–0.95) |
0.02 |
0.10 (0.04–0.23) |
< 0.001 |
| C-reactive proteina |
1.01 (1.01–1.02) |
0.002 |
1.01 (1.01–1.02) |
0.001 |
| RF IgM-positivea, b |
0.96 (0.79–1.17) |
0.67 |
||
| Anti-CCP-positivea, b |
0.90 (0.74–1.10) |
0.30 |
||
| Gluocorticoid usera, b |
1.17 (0.94–1.48) |
0.16 |
||
| DMARD usera, b |
1.04 (0.85–1.26) |
0.71 |
||
| NSAID usera, b |
0.97 (0.80–1.19) |
0.81 |
||
| Ritchie scorea |
1.01 (0.99–1.03) |
0.21 |
||
| HAQa |
1.06 (0.90–1.24) |
0.47 |
||
| Sharp scorea |
1.00 (0.99–1.02) |
0.93 |
||
| Disease durationa |
0.99 (0.91–1.08) |
0.82 |
||
| Age × male gender |
1.04 (1.02–1.05) |
< 0.001 |
||
|
|
||||
| R2 adjusted |
0.23 |
< 0.05 |
||
|
aAge- and gender-adjusted; bdichotomized variable. anti-CCP, anti-cyclic citrullinated peptide antibody; DMARD, disease-modifying anti-rheumatic drug; HAQ, Stanford Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria. | ||||
Provan et al. Arthritis Research & Therapy 2008 10:R70 doi:10.1186/ar2442 |
||||